A carregar...
Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report
The efficacy and safety of osimertinib have been demonstrated in several clinical trials; however, acquired resistance is an inevitable problem associated with most targeted drugs. Based on previous findings, the mechanism of osimertinib resistance is equivocal, and there is still no consensus on th...
Na minha lista:
| Publicado no: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7082283/ https://ncbi.nlm.nih.gov/pubmed/32206561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2020.01.10 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|